Home » Announcement of Shanghai Ailis Pharmaceutical Technology Co., Ltd. on matters needing attention in participating in the first extraordinary general meeting of shareholders in 2022 during the epidemic prevention and control period | Shanghai_Sina Finance_Sina.com

Announcement of Shanghai Ailis Pharmaceutical Technology Co., Ltd. on matters needing attention in participating in the first extraordinary general meeting of shareholders in 2022 during the epidemic prevention and control period | Shanghai_Sina Finance_Sina.com

by admin
Announcement of Shanghai Ailis Pharmaceutical Technology Co., Ltd. on matters needing attention in participating in the first extraordinary general meeting of shareholders in 2022 during the epidemic prevention and control period | Shanghai_Sina Finance_Sina.com


Stock code: 688578 Stock abbreviation:Ellis Announcement No.: 2022-006

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Shanghai Ellis Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the “Company”) published the “Shanghai Ellis” on the website of the Shanghai Stock Exchange (http://www.sse.com.cn) on March 12, 2022. The Notice of Pharmaceutical Technology Co., Ltd. on Convening the First Extraordinary General Meeting of Shareholders in 2022, scheduled to be held on March 28, 2022 at No. 1227 Zhangheng Road and No. 1118 Harley Road, China (Shanghai) Pilot Free Trade Zone, 5th Floor, Building 1 The first extraordinary general meeting of shareholders in 2022 will be held in the large conference room. The voting method adopted at this general meeting of shareholders is a combination of on-site voting and online voting.

As Shanghai is currently in the period of new crown pneumonia epidemic prevention and control, in accordance with the requirements of government departments for epidemic prevention and control, the area where the shareholders’ meeting will be held is subject to closed management. In order to protect the health and safety of shareholders, shareholders’ agents and other participants, and In order to protect the legitimate rights and interests of shareholders in accordance with the law, the company has specially reminded the following points for attention to participating in this general meeting of shareholders during the epidemic prevention and control period:

See also  Dalian, Liaoning: There are 198 centralized quarantine places, 22195 people in quarantine

1. It is recommended to choose the online voting method to participate in the meeting first

In order to cooperate with the epidemic prevention and control work, protect the health of shareholders, shareholders’ proxies and other participants, reduce the gathering of people, and reduce the risk of infection, it is recommended that shareholders choose to participate in this shareholders’ meeting through online voting.

2. Adjust the on-site meeting method to communication method

Due to the requirements of epidemic prevention and control, the meeting site cannot be set up at the meeting place for this general meeting, and the on-site meeting method is adjusted to be held by means of communication. Registered shareholders and shareholders’ proxies will not be able to access this meeting, and can participate in this shareholders’ meeting through online voting). The holding time and deliberation items of the first extraordinary general meeting in 2022 remain unchanged.

Special announcement.

Board of Directors of Shanghai Alys Pharmaceutical Technology Co., Ltd.

March 26, 2022

Massive information, accurate interpretation, all in Sina Finance APP

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy